BOSTON SCIENTIFIC, GUIDANT AWAIT APPROVAL
If it hopes to stay on track with its acquisition timetable, Boston Scientific
Corp. has about six weeks to complete its $27.2 billion deal to buy medical
device maker Guidant Corp. But so far, the companies are still awaiting regulatory
approval in the U.S. and Europe as well as the endorsement of shareholders.
Boston Scientific spokesman Paul Donovan said Tuesday both companies plan to
have shareholder votes on the cash-and-stock deal by the end of next month.
Casper Star Tribune